StockNews.com assumed coverage on shares of VolitionRx (NYSE:VNRX – Free Report) in a research note published on Thursday. The firm issued a sell rating on the stock.
Separately, Cantor Fitzgerald restated an overweight rating and set a $2.50 price target on shares of VolitionRx in a research report on Wednesday, March 27th.
Get Our Latest Research Report on VNRX
VolitionRx Trading Up 3.9 %
VolitionRx (NYSE:VNRX – Get Free Report) last issued its quarterly earnings data on Monday, March 25th. The company reported ($0.11) earnings per share for the quarter. The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.50 million. Research analysts predict that VolitionRx will post -0.4 earnings per share for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in VolitionRx stock. Silverberg Bernstein Capital Management LLC purchased a new position in shares of VolitionRx Limited (NYSE:VNRX – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 147,038 shares of the company’s stock, valued at approximately $105,000. Silverberg Bernstein Capital Management LLC owned 0.19% of VolitionRx as of its most recent SEC filing. Hedge funds and other institutional investors own 8.09% of the company’s stock.
About VolitionRx
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening blood test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.
See Also
- Five stocks we like better than VolitionRx
- What Is WallStreetBets and What Stocks Are They Targeting?
- Comprehensive PepsiCo Stock Analysis
- What is the S&P/TSX Index?
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Bear Market Funds to Watch This Year
Receive News & Ratings for VolitionRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRx and related companies with MarketBeat.com's FREE daily email newsletter.